Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) continues yesterday’s fall even in today’s pre-market. Where will it stop?
Cyclerion Therapeutics a clinical-stage biopharmaceutical company. It engages in the discovering, development, and commercialization of medicines for serious central nervous system disorders. The Cambridge-based company’s product portfolio includes CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy.
CYCN To Present At Conference
Cyclerion Therapeutics announced that the company’s management will present a corporate overview at the Jefferies Virtual Healthcare Conference on 1st June.
- Investors may request a meeting through Jefferies and Management will also be available for one-on-one meetings
- CYCN‘s live webcast can be accessed via the Investors & Media section.
CYCN is trading at $2.95 in its pre-market session with volume of almost 567K million.
Important Pivot Points